No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer-Reference-Cited by-同舟云学术

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer

Published:2018-10-03 Issue:6 Volume:82 Page:1061-1066
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kosaka Takeo^ORCID,Hongo Hiroshi,Watanabe Keitaro,Mizuno Ryuichi,Kikuchi Eiji,Oya Mototsugu

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3698-1/fulltext.html

Reference16 articles.

1. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

2. Mita AC, Denis LJ, Rowinsky EK et al (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723–730

3. Pivot X, Koralewski P, Hidalgo JL et al (2008) A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547–1552

4. Pezaro CJ, Omlin AG, Altavilla A et al (2014) Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 66:459–465

5. Al Nakouzi N, Le Moulec S, Albiges L et al (2015) Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 68:228–235

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-12-15

2. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis;Urologic Oncology: Seminars and Original Investigations;2023-04

3. The efficacy of sequential therapy with docetaxel and cabazitaxel for castration‐resistant prostate cancer: A retrospective multi‐institutional study in Japan;International Journal of Urology;2022-11-14

4. Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study;Prostate International;2021-06

5. Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report;American Journal of Case Reports;2021-05-26